Skip to main content
. 2022 Sep 26;11(1):2124058. doi: 10.1080/2162402X.2022.2124058

Figure 2.

Figure 2.

Generation of CAR-T cells for anti-DMG therapy. CAR-T cells present a powerful new approach to precision immunotherapy in DMG. CAR-T cells are generated from a DMG patient’s own T cells (a) and directed against tumor-specific antigens/neoantigens by genetic introduction of a chimeric antigen receptor (CAR) gene (b). Clonally expanded CAR T cells (c) are then reinfused into the originating patient and are activated to promote enhanced tumor cell-specific destruction (d). Treatment of 4 DMG patients with GD2-directed CAR-T cells recently demonstrated both radiologic and clinical benefit, evidencing the transformative potential of this novel therapy.